A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

So far, 4.2 million animal tests under the REACH chemical regulation: A study from Konstanz and Baltimore quantifies the number of animals that died for the hazard assessment of chemicals in the chemical industry.

On Tuesday, July 18, 2023, the Tübingen AI Center held a symposium to celebrate its permanent establishment as a national AI center. Since July 1, 2022, it has received 20 million euros a year in funding from the federal government and the state.

Expert interview - 28/06/2023

Money isn't all that is needed – knowledge and networking can also help start-ups move forward

Dr. Rolf Neuhaus is one of the driving forces behind PALATINA Business Angels Rhein-Neckar e.V., a business angels association in the Rhine-Neckar metropolitan region. In an interview with BIOPRO, Neuhaus describes the association’s activities and explains where there is still catching up to be done in terms of start-up support in Baden-Württemberg.

Detecting drug resistance of tumour cells - 25/05/2023

AI-assisted diagnostics declares war on lung cancer

Lung cancer is one of the most common cancers and has a particularly high mortality rate. A significant challenge in treating this disease lies in the resistance of lung tumours to conventional drug therapies, rendering chemotherapy ineffective. There is hope on the horizon as a team of experts from Baden-Württemberg has joined forces to develop an innovative AI-supported test procedure that paves the way for individualised therapy approaches.

Heidelberg University is to acquire a research building to develop innovative engineering science strategies and technologies on the basis of life-inspired molecular systems. The German Science and Humanities Council has now expressed its backing for the idea with an outstanding rating. This recommendation is the crucial precondition for a new building on the university campus Im Neuenheimer Feld.

The Phytopharmaceuticals and Valuable Plant Ingredients initiative aims to further develop phytopharmaceuticals and valuable plant ingredients in Baden-Württemberg.

Press release - 31/03/2023

Simulation of Miscanthus- and Sorghum-based resilient value chains in the Danube Region

Can the value chains in the Danube macro-region be more sustainable and resilient against disruptions such as pandemics? How modelling could help to simulate the economic viability of developing Miscanthus and Sorghum based value chains in that region?

Expert interview - 08/03/2023

How do new active substances from university research reach patients?

Access to capital remains one of the biggest challenges in the life sciences sector. Over the last two years, the Baden-Württemberg Center for Academic Drug Discovery (BWCAD2) has successfully implemented a model of cooperation between academic drug research and industry for the development and validation of therapeutic concepts. Dr. Barbara Jonischkeit spoke with the initiator and leading figure behind the BWCAD2 project, Prof. Dr. Stefan Laufer

This month marks the launch of an outstanding project integrating artificial intelligence (AI) and neuromedicine – the Hertie Institute for Artificial Intelligence in Brain Health (Hertie AI). Founded on February 1 at the Medical Faculty of the University of Tübingen, it will be the first institute in Germany to research the prevention and early diagnosis of diseases of the nervous system using artificial intelligence methods.

Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.

Non-profit limited liability company creates institutional framework for interdisciplinary research collaboration, innovative technology development and outstanding healthcare in the Rhine-Neckar region.

Photon-counting technology - 01/02/2023

PC3 consortium: innovative computed tomography for Baden-Württemberg

The University Hospitals of Freiburg, Tübingen and Mannheim have been cooperating with each other since 2021 to test new types of computed tomography devices. With the help of photon-counting technology, the aim is not only to improve patient care, but also to encourage local companies to develop downstream data processing technologies.

Press release - 16/01/2023

GoDanuBio’s contribution to the bioeconomisation of the Danube Region

GoDanuBio supported the set-up of policy frameworks and participative governance schemes in the participating regions. The main topics were circular bioeconomy, sustainable rural development and rural-urban interactions.